The emergence of HER2-low therapies for metastatic breast cancer is a paradigm shift in the traditional binary classification of a patient’s HER2 status, creating a need for practice changes in pathology necessitated by the expansion in how HER2-low breast cancer needs to be classified and treated. During this recorded 2022 ASCP Annual Meeting session, a moderated expert faculty panel discussed evolving and emerging trends in breast cancer classification and reporting across the HER2+ spectrum. They also discussed how pathologists and laboratory professionals can prepare for HER2-low classification, tracking, and reporting. In addition, they reviewed some of the current challenges in HER2 testing and explored opportunities to prepare for the future landscape of HER classification in breast cancer. This activity is supported by educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.